A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 May 2017
At a glance
- Drugs AZD-1775 (Primary) ; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 24 May 2017 Planned End Date changed from 1 Jun 2018 to 27 Jun 2018.
- 24 May 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2017 Status changed from active, no longer recruiting to recruiting.